Clinical Studies on Tabex® Cytisine
“Robert West of University of College London studies quitting patterns. Robert’s study in 2011 showed Tabex® can increase your chances of giving up by fourfold”
“People taking Tabex® cytisine are less likely to smoke than NRT, says research”
Clinical Studies on Tabex® Cytisine Tablets
Tabex® cytisine was clinically tested on a large number of patients. Stoyanov S. and Yanachkova M. one of the founders of Cytisine studied 70 volunteers with a long experience in smoking cessation and found that 57% of patients stopped smoking in 31.4% the result was partial: reduction of the cigarettes smoked from 20-30 to 3-4 per day. Results were negative in 11% of patients which is due to the premature stopping of Tabex: before the 3rd day of treatment – a period of time necessary to saturate the organism with cytisine.
In a second group of 17 smokers with serious psychic diseases (schizophrenia, epilepsy psychosis), the administration of Tabex® together with neuroleptics, antidepressants and insulin led 5 patients to stop smoking and induced significant decrease. Therefore tabex® does not interact in favor with the drugs received by the groups of patients.
Vlaev S. et al. considers the possibility to control the depressive symptoms in 5 patients with psychogenic and periodic depression in Tabex dosage and application. Tabex® was applied gradually increasing doses, the maximum daily dose being 15 mg (5 tablets 3 times daily). A rapid reduction of the depressive symptoms, the improvement of patients with reactive depression being obtained at the end of week one. In patients with periodic depression – by the end of the second week. As a side effect, the slight internal tension and a slight decrease of blood pressure are pointed out. The antidepressive action of the drug is explained with the increase of the catecholamine level, especially adrenaline which is reduced in patients with depression. The adrenostimulating effect of Tabex® has been well known for a long time, but its antidepressive activity is reported by Antonov L. and V. Velkov.
The effect of the treatment with Tabex® cytisine in the Friedrichsheim Hospital in Berlin shows a decrease of the number of smokers who have given up smoking with Tabex cytisine.
The antidepressant action is confirmed by schizophrenic psychosis in two patients who have received Tabex® cytisine in a state of remission. The effect is similar to the application of the antidepressant psychoforin of schizophrenic patients. These data are confirmed by Stoyanov and Yanachkova in psychic patients. The authors state that a form of depression is appropriate for Tabex® treatment with very careful increase of the daily doses.
Paun D. and Franze J. from the Friedrichscheim Hospital in Berlin studied the therapeutic effectiveness of Tabex® in 266 smokers, by comparing it to a 239 placebo group. Results were followed on the 4th, 8th, 13th and 26th week after using Tabex®. Patients with a serious intention to give up smoking have priority. On the 8th week, 55% of the patients treated with Tabex® gave up smoking, this percentage decreasing to 26% at the end of the 26th week. The recidivists in the main group decreased twice the number of cigarettes consumed. The authors show the outstanding results of those treated with Tabex® compared to the group treated with placebo and conclude that Tabex may be successfully used when the patient has a serious intention to give up smoking.
Clinical Studies of Tabex were also undertaken with Tabex® given to 366 smokers with bronchitis and 239 patients treated with placebo. After completing the full course (maximum duration 4 weeks), 55% of the patients gave up smoking, and the group with placebo there was an effect in only 34%.
Out of 230 smokers with bronchitis treated with Tabex® 85% gave up smoking with Tabex by the end of the 4th week, and after 8 weeks – 66% and after 23 weeks – 46%. These results have been well documented and used in further clinical studies.
Following is the treatment with Tabex® Cytisine in a risk group of smokers (with diagnosed chronic bronchitis) in Berlin and Potsdam
Schmidt F. conducted volume testing of 14 preparations on 1975 smokers by means of a double-blind placebo-controlled experiment. Tabex® was given to 181 patients overall. Results show that patients treated with Tabex® have had optimum improvement. 103 patients (157%) gave up smoking after 3 months this percentage where it decreased to 38%. Tabex® is followed by using the drugs niperli (54% and 48% respectively), atabaco (54% and 29% respectively), citotal (50% and 36% respectively), unilobin, potassium chloride, potassium granulate, potassium citrate, nicobrevin, targophagin, etc.
All volunteers received by mail the method of using Tabex as to avoid the influence of the extrapharmacological circumstances therefore results registered by the patients themselves in inquiry forms are maximally reliable.
On the basis of the multi-center clinical-pharmacological studies, we can make the following general conclusions concerning the therapeutic effectiveness of Tabex®:
- The drug Tabex® was tested on 1045 volunteers and compared to 400 patients treated with placebo and 1500 patients treated with other anti-smoking drugs. The results obtained show that 55 to 76% of the patients treated with Tabex® gave up smoking. These generalized percentages from different studies are statistically significant and are higher that those of the other preparations compared.
- Tabex® showed a maximum effect on the chronic pulmonary diseases accompanying prolonged smoking, as well as on patients with psychic diseases of a depressive nature.
- No serious side effects have been noticed by using Tabex Cytisine.
- An improvement of the general state of the patients was observed due to the discontinuation nicotine.
- Note: 2 month cycle benefits. Patients who have failed during the first course should repeat the course on the second month (Tabex is always recommended to be cycled twice for maximum benefits) . If this fails repeat the course at intervals of 4 to 5 months whilst making the conscious effort to stop smoking with Tabex inbetween.